RxDoctor Payments Data

Joseph Mahon, MD

Urology · Edina, MNNPI 1295171072

Payments from drug & device makers

What this record shows

This record is dominated by grants: $60,000 of the $85,935 with a category attached, or 69.8%. Boston Scientific accounts for 76.0% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2019 at $62,305 and has fallen 94.6% since, to $3,378 in 2025. Among urology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$85,935in general payments, 2019–2025

Across 306 payments — averaging $280.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$65K
  • Coloplast$15K
  • Axonics, Inc.$736
  • SRS Medical Systems, Inc.$543
  • Dendreon Pharmaceuticals LLC$524
  • Procept Biorobotics Corporation$474
  • plus $3K from 39 others

What the payments were for

  • Consulting fees$14,75117%
  • Speaking & faculty fees$1220%
  • Grants$60,00070%
  • Travel & lodging$5361%
  • Food & beverage$10,47412%
  • Entertainment$520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$85,935 in reported general payments places this provider in the 95th percentile of 247 urology providers in Minnesota.

See all urology providers in Minnesota

Medicare billing

Part B allowed, 2024
$215,827
Medicare patients
279
Services billed
16,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron38$30,794
GemtesaVibegron20$16,110
XyostedTestosterone Enanthate14$8,542
Finasteride309$5,322
Testosterone23$4,867
Oxybutynin Chloride ErOxybutynin Chloride151$4,510
Trospium Chloride ErTrospium Chloride21$3,577
Tamsulosin Hcl221$3,406
Alfuzosin Hcl ErAlfuzosin Hcl83$2,115
Methenamine Hippurate35$1,557
Testosterone Cypionate42$1,408
Cabergoline15$1,318
Trospium Chloride19$1,089
Pentoxifylline23$1,012
Tolterodine Tartrate ErTolterodine Tartrate16$826

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$136$30,79438 claims
Sumitomo Pharma America, Inc.Gemtesa$18$16,11020 claims
Antares Pharma, Inc.Xyosted$267$8,54214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 247 urology providers in Minnesota.

Other urology in Edina

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →